Literature DB >> 14697915

Evaluation of bone mineral density in inflammatory bowel disease: current safety focus.

Gary R Lichtenstein1.   

Abstract

Crohn's disease and ulcerative colitis constitute a group of disorders collectively known as inflammatory bowel disease. Men and women are equally affected, and no socioeconomic classes are spared. The age of disease onset is relatively young, frequently in the second and third decade of life. The constellation of nonspecific symptoms that constitute the prototypic symptoms of patients afflicted with inflammatory bowel disease are often overlooked and not attributed to their correct origin. These multisystem disorders commonly involve the musculoskeletal system. The skeletal system can be involved by the disease itself or by the medications used in the treatment of the disease. The finding of abnormal bone mineral density in patients with either ulcerative colitis or Crohn's disease is a relatively commonplace finding. This review discusses the pathophysiology involved in the formation of abnormal bone mineral density and the treatment of this condition in patients with inflammatory bowel disease.

Entities:  

Mesh:

Year:  2003        PMID: 14697915     DOI: 10.1016/j.amjgastroenterol.2003.11.003

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  2 in total

1.  Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion.

Authors:  R E Kast; E L Altschuler
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 2.  Drug therapy for ulcerative colitis.

Authors:  Chang-Tai Xu; Shu-Yong Meng; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.